返回 Agenda
Session Chair(s)
Doug Kornbrust, PHD
President
Preclinsight, United States
Shwu-Luan Lee, PHD
Pharmacologist, Office of New Drug, CDER
FDA, United States
Speaker(s)
Considerations in Assessment of Reproductive and Developmental Risk for Oligonucleotide-based Therapies
Tacey E. White, PHD
Aclairo, Inc, United States
Senior Consultant
Final Recommendations of the OSWG Genetox Subcommittee: Standard Battery and Beyond
Cindy L. Berman, PHD
Berman Consulting, United States
Independent Consultant
Measurement and Prediction of Hybridization-induced Off-target Effects of Oligonucleotide Drug Candidates
Morten Lindow, PHD
Santaris Pharma A/S, Denmark
Group Leader, Integrative Systems Biology
Panelist
David H. Schubert
United States
Panelist
Jennifer Marlowe, PHD
bluebirdbio, United States
Senior Director, Preclinical Development
Panelist
Arthur A. Levin, PHD
Avidity Biosciences, United States
Distinguished Scientist
Panelist
Scott Henry, PHD
Ionis Pharmaceuticals, Inc., United States
Senior Vice President, Nonclinical Development
Panelist
Rosanne Seguin, PHD
McGill University, Canada
Panelist
Cindy L. Berman, PHD
Berman Consulting, United States
Independent Consultant